Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
Rimegepant sulfate hydrate is the hydrated salt form of rimegepant, a potent and selective small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. With the CAS number 2146389-75-7, this compound serves as a critical pharmaceutical intermediate and active ingredient in migraine therapeutics. Its molecular formula corresponds to that of the free base combined with sulfuric acid and water molecules, typically represented as C₂₅H₂₉N₇O₄S·H₂SO₄·xH₂O, though exact hydration levels may vary based on crystallization conditions.
The primary clinical application of Rimegepant sulfate hydrate lies in the acute treatment of migraine attacks with or without aura in adults. Unlike traditional triptans, which act as serotonin receptor agonists and carry cardiovascular risks, CGRP antagonists offer a novel mechanism by blocking the neuropeptide responsible for transmitting pain signals and causing neurogenic inflammation during a migraine episode. This unique profile allows patients who cannot tolerate other treatments to find relief without vasoconstriction concerns. Furthermore, emerging data suggests potential utility in the preventive management of episodic migraines when administered every other day.
As a key raw material for drug manufacturing, Rimegepant sulfate hydrate must meet rigorous purity standards to ensure safety and efficacy in final dosage forms, such as orally disintegrating tablets. The hydrate form is often preferred in formulation development due to its enhanced stability and favorable physicochemical properties compared to the anhydrous counterpart. By targeting the CGRP pathway specifically, this molecule represents a significant advancement in neurology, offering rapid onset of action and a high tolerability profile. It has revolutionized migraine care by addressing a long-standing unmet need for non-opioid, non-triptan options that minimize side effects while effectively aborting severe headache episodes. Continued research into this compound underscores its importance in modern pharmacotherapy for neurological disorders affecting millions globally.